Tempus AI, Inc. has reported its financial results for Q2 2025, demonstrating significant revenue growth and improvements in key metrics.
Financial Results for Q2 2025
Tempus AI, Inc. reported revenues of $314.6 million, an increase of 89.6% compared to the same period last year. The expected revenue was $297.8 million. Gross profit also saw a remarkable increase of 158.3%, reaching $195 million compared to $75.5 million in Q2 2024.
The company's net loss for the quarter was $42.8 million, a significant improvement from the net loss of $552.2 million recorded in the same quarter last year. The net loss per share was $0.25, in line with expectations and showing a stark improvement from the $6.86 loss per share in Q2 2024.
Optimistic Outlook for Upcoming Quarters
Tempus AI has raised its full-year 2025 revenue guidance to approximately $1.26 billion, reflecting an anticipated 82% annual growth. The company also expects an adjusted EBITDA of $5 million for the full year, representing an improvement of approximately $110 million over 2024. This optimistic outlook is supported by Tempus AI’s strategic initiatives and financial flexibility.
The recent issuance of $750 million of convertible senior notes has enhanced the company’s balance sheet, allowing it to replace a portion of its existing term loan with lower interest debt.
Innovations and Company Development
Tempus AI continues to expand its AI-powered clinical tools, extending its Tempus Next! care pathway intelligence platform into breast cancer and integrating its Tempus One AI clinical assistant into leading electronic health record systems. These advancements, along with the introduction of Tempus xM for treatment and response monitoring, demonstrate the company’s commitment to innovation and its potential for sustained growth.
The financial results of Tempus AI for Q2 2025 highlight its growth and commitment to innovation in the field of medical technologies, contributing to its ongoing development.
